Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2622
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration ; volume:144 ; number:2 ; day:26 ; month:2 ; year:2022 ; pages:99-115 ; date:4.2022
Documenta ophthalmologica ; 144, Heft 2 (26.2.2022), 99-115, 4.2022
- Urheber
-
Schroeder, Marion
Kjellström, Ulrika
Lövestam-Adrian, Monica
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10633-021-09863-7
- URN
-
urn:nbn:de:101:1-2022070521515041927983
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schroeder, Marion
- Kjellström, Ulrika
- Lövestam-Adrian, Monica
- SpringerLink (Online service)
Ähnliche Objekte (12)
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration